Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161 Filed. | May 4, 2023
Arbutus Biopharma (ABUS) Provides AB-729 Clinical Data and AB-161 Preclinical Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update - read this article along with other careers information, tips and advice on BioSpace
01.11.2022 - HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide enhanced . Seite 1